Earlier this month, a study was released for Abiraterone, a new drug from J&J that it is one of four drugs to ever demonstrate a survival benefit for patients with advanced prostate cancer. The study claimed that in a sample of 1,195 patients given the drug plus a low-dose steroid lived 14.8 months while those given a low-dose steroid plus a placebo survived 10.9 months. (more…)
Author Archive
Searching for the Holy Grail of Prostate Cancer, October 19th, 2010
Free Diagnostic Imaging?, July 18th, 2010
Free preventive care should help the US curb the rapid proliferation of chronic conditions such as cardiovascular disease and catch cancer sooner. I’ve been told over the years by numerous clients that the majority of costs associated with chronic diseases are incurred toward the end of life. It is ideal if these diseases can be identified and treated in early stages. (more…)
Frankenbug: The First Synthetic Bacterium, June 1st, 2010
Although it’s difficult to pinpoint an exact date, it’s safe to say that society became enthralled with the notion of molecular medicine and synthetic biology somewhere between the release of Gattaca and the completion of the Human Genome Project. (more…)